Pancreatic Cancer Research

ResearcherJiangnan UniversityActive in the last 2 years

Hao Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8663-8176; OpenAlex author ID A5008351243. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2025: 3 papers

Papers 3

  1. NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated LAMB3-mediated FAK/ERK pathway. Last author DOI 10.1002/cac2.70045↗
  2. UGT1A6 in pancreatic cancer: a promising prognostic biomarker and therapeutic target. Last author DOI 10.1007/s12094-025-03976-0↗
  3. Targeting the ac4C 'Writer' NAT10 enhances pancreatic cancer immunotherapy via dual modulation of CD8+ T cells and tumor cells. Last author DOI 10.1038/s41419-025-08156-0↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuo Zhang · 2 shared papers, 2025 · strength 0.45
  2. Leisheng Wang · 2 shared papers, 2025 · strength 0.45
  3. Enhong Chen · 2 shared papers, 2025 · strength 0.45
  4. Xianping Lu · 1 shared paper, 2025 · strength 0.25
  5. Shudong Hu · 1 shared paper, 2025 · strength 0.22
  6. Hao Ye · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.